Vir Biotechnology Inc (VIR)
9.645
+0.28
(+2.93%)
USD |
NASDAQ |
Nov 05, 16:00
9.645
0.00 (0.00%)
After-Hours: 16:08
Vir Biotechnology Enterprise Value: 366.46M for Nov. 4, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 04, 2024 | 366.46M |
| November 01, 2024 | 351.43M |
| October 31, 2024 | 109.46M |
| October 30, 2024 | 124.49M |
| October 29, 2024 | 125.86M |
| October 28, 2024 | 145.00M |
| October 25, 2024 | 108.09M |
| October 24, 2024 | 90.32M |
| October 23, 2024 | 113.56M |
| October 22, 2024 | 125.86M |
| October 21, 2024 | 131.33M |
| October 18, 2024 | 128.60M |
| October 17, 2024 | 140.90M |
| October 16, 2024 | 161.41M |
| October 15, 2024 | 145.00M |
| October 14, 2024 | 134.06M |
| October 11, 2024 | 123.13M |
| October 10, 2024 | 88.95M |
| October 09, 2024 | 87.58M |
| October 08, 2024 | 86.22M |
| October 07, 2024 | 97.15M |
| October 04, 2024 | 143.63M |
| October 03, 2024 | 87.58M |
| October 02, 2024 | 135.43M |
| October 01, 2024 | 119.03M |
| Date | Value |
|---|---|
| September 30, 2024 | 109.46M |
| September 27, 2024 | -122.17M |
| September 26, 2024 | -153.60M |
| September 25, 2024 | -159.06M |
| September 24, 2024 | -120.80M |
| September 23, 2024 | -112.60M |
| September 20, 2024 | -90.74M |
| September 19, 2024 | -66.15M |
| September 18, 2024 | -85.28M |
| September 17, 2024 | -67.51M |
| September 16, 2024 | -75.71M |
| September 13, 2024 | -42.92M |
| September 12, 2024 | -77.08M |
| September 11, 2024 | -81.18M |
| September 10, 2024 | -60.68M |
| September 09, 2024 | -82.54M |
| September 06, 2024 | -90.74M |
| September 05, 2024 | -105.77M |
| September 04, 2024 | -112.60M |
| September 03, 2024 | -88.01M |
| August 30, 2024 | -22.42M |
| August 29, 2024 | -16.96M |
| August 28, 2024 | -21.06M |
| August 27, 2024 | -10.12M |
| August 26, 2024 | 26.77M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-652.67M
Minimum
Oct 27 2023
9.848B
Maximum
Jan 27 2021
2.199B
Average
1.522B
Median
Feb 07 2023
Enterprise Value Benchmarks
| Pfizer Inc | 219.16B |
| Biomarin Pharmaceutical Inc | 12.24B |
| Arbutus Biopharma Corp | 586.71M |
| GlycoMimetics Inc | 4.052M |
| FibroGen Inc | 6.090M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -213.72M |
| Revenue (Quarterly) | 0.289M |
| Total Expenses (Quarterly) | 218.88M |
| EPS Diluted (Quarterly) | -1.56 |
| Gross Profit Margin (Quarterly) | 82.70% |
| Profit Margin (Quarterly) | -73.95K% |
| Earnings Yield | -40.64% |
| Normalized Earnings Yield | -37.57 |